A team of Argentine scientists, led by doctors Mariana Salatino and Claudia Lanari, members of the scientific program of the SALES Foundation and CONICET are developing research that would allow, in the future, to treat luminal breast cancer with immunotherapy.
Historically, breast cancer was not a good candidate for the application of immunotherapies, among other reasons, because it did not present many mutations and generate few antigens – molecules that call the attention of the immune system. The results obtained by the researchers propose an alternative that would make it possible for hormone-dependent tumors to respond to immunotherapy.
“In breast cancer, there are three large groups: hormone-dependent or luminal tumors, HER2 positive and triple negative. In the clinic, immunotherapy is approved only for the triple negative subgroup, in combination with chemotherapy. What we are proposing is that, perhaps in the future, patients with tumors of the luminal subtype could benefit from immunotherapy in combination with mifepristone, which is an endocrine therapy ”, says Salatino.
In addition to Lanari and Salatino, the work includes Gonzalo Sequeira, Ana Sahores and Tomás Dalotto-Moreno. Along with them, the fellows Ramiro Perrotta and Gabriela Pataccini, the researchers Caroline Lamb, Maria Laura Polo and Virginia Novaro, the pathologist Silvia Vanzulli and Dr. Gabriel Rabinovich. This new research has already been recognized by the prestigious journal Cancer Research.
***
Javier Blanco Asset.comm
–
– .
